MPMikołaj Porzak

Mikołaj Porzak

*This is an algorithmically generated author record based on publicly available information.

Mikołaj Porzak has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Small intestinal bacterial overgrowth – current, novel and possible future methods of treatment and diagnosis

    by Mateusz Sobczyk, Mikołaj Porzak, Daria Żuraw, Alicja Sodolska, Paulina Oleksa, Kacper Jasiński

    Small intestinal bacterial overgrowth (SIBO) is a prevalent issue, frequently overlooked in clinical practice. Its prevalence is unknown because SIBO requires diagnostic testing, however, in most studies, SIBO has been detected anywhere from <2% to 22% of healthy controls. Breath tests, which detect the presence of hydrogen in exhaled air, are the most used diagnostic method. However, their low sensitivity and specificity indicate the need for research into new more accurate methods. The standard treatment is antibiotic therapy with rifaximin. After antibiotic therapy, there is a risk of recurrence and the emergence of multidrug-resistant bacterial strains. Recurrence ratio after antibiotic therapy have been documented in 12.6% of patients after 3 months, 27.5% after 6 months and 43.7% after 9 months. There are promising results from studies on the use of probiotics and herbal preparations in treatment, but these studies have been conducted on relatively small groups of patients. This indicates the need for multicentre randomised trials with large numbers of patients to develop effective methods for the diagnosis and treatment of SIBO.


  • Open Access

    Antibiotics use, urgency and beliefs about antibiotics in the case of acute pharyngitis

    by Mikołaj Porzak, Mateusz Sobczyk, Magdalena Kubicka-Dębiec, Robert Porzak

    Introduction and objective: The study investigates patterns of antibiotic use among patients in the Lublin area of eastern Poland, aiming to understand the motivations behind self- -medication. Specifically, the study focuses on identifying repeatable patterns of antibiotic use and assessing...


  • Open Access

    Risk factors of self-medication with antibiotics for acute pharyngitis

    by Mikołaj Porzak, Michał Dacka, Mateusz Sobczyk, Alicja Sodolska, Daria Żuraw, Kacper Jasiński, Paulina Oleksa, Robert Porzak, Magdalena Kubicka-Dębiec

    Background: Self-medicating with antibiotics is prevalent in low- and middle-income nations. This research sought to assess the perspectives on antibiotic usage and self-medication in case of acute pharyngitis, as well as the factors linked to self-medication among patients of a family doctor's clinic in Lublin, Poland. Methods: A original, fully anonymous survey was conducted among patients of a family doctor's clinic in Lublin. The descriptive statistics of answers in questionnaires and Automatic Linear Modeling Regression (LINEAR) was applied to point out the most significant predictors of the antibiotics misuse. Results: A response number of 262 participants was obtained. About 15,6% (41/262) respondents had self-medicated during the last year due to acute pharyngitis symptoms. We have identified the following important risk factors of anti-health behaviours connected with self-medication: frequent occurrence of symptoms of acute pharyngitis, frequent receiving antibiotics on prescription, frequent diagnosing a bacterial cause of sore throat, higher sensitivity to pain and lower education level. Surprisingly our research shows that women present lower sensitivity to pain than men in case of pain connected with acute pharyngitis. Conclusion: There is a need for greater attention paid to the education of the patients presenting the aforementioned risk factors. Education should focus on the risks to the patients connected with antimicrobial resistance.

  • Open Access

    Frontotemporal Dementia: A Clinical Review

    by Michał Dacka, Mikołaj Porzak, Karol Bochyński, Konrad Białogłowski, Paulina Dąbrowska, Michał Żuber, Katarzyna Ciuba, Katarzyna Molenda, Filip Borodziuk, Barbara Borodziuk

    Frontotemporal dementia is a disease in which atrophic changes occur in the frontal lobes and frontal temporal lobes of the brain. Frontotemporal dementias are a clinically, neuroanatomically and pathologically diverse group of diseases that collectively constitute an important cause of young-onset dementia. The most common form of frontotemporal dementia is the so-called behavioral variant of frontotemporal dementia. Underlying these pathological changes is the degeneration of nerve cells (i.e. neurons), which occurs through the accumulation of abnormal proteins inside them. Therefore, the review of current studies in the subject of Frontotemporal dementia was conducted in order to access possible risk factors and new ways of management and treatment of this complex disease.


  • Open Access

    SGLT2 inhibitors and their possible use in prevention and treatment of neurological diseases

    by Mateusz Sobczyk, Daria Żuraw, Paulina Oleksa, Kacper Jasiński, Mikołaj Porzak, Michał Dacka

    Neurological diseases, neurological complications of diabetes and cardiovascular disease complications affecting the central nervous system (CNS) are one of the greatest challenges of modern medicine. Many of these diseases require the introduction of new therapies to improve the prognosis and quality of life of patients. Drugs with the increasing use in recent years are the SGLT2 inhibitors (SGLT2i): canagliflozin, dapagliflozin, empagliflozin. They demonstrate multiple pleiotropic actions with potential applications in CNS diseases. In addition to renal tubules, SGLT receptors are also found within the central nervous system. In numerous studies in animal models, SGLT2i have had promising results in the treatment of neurological conditions such as Alzheimer's disease, autism spectrum disorders, lesions caused by vascular diseases or complications of ischaemic stroke. SGLT2 inhibitors reduce oxidative stress and activation of inflammatory processes within the CNS, which may in the future be used to treat neurological diseases. So far, published studies on the effects of SGLT2 inhibitors on the nervous system are promising, but extensive, multicentre randomised trials on large groups of patients are needed to understand the exact mechanisms of action, therapeutic effects and potential side effects of SGLT2i.


  • Open Access

    Toxic substances in the household - cases of poisoning, therapy, complications

    by Joanna Wilk, Magdalena Kubicka, Paweł Dębiec, Przemysław Szydłowski, Magdalena Makarewicz, Mikołaj Porzak, Natalia Szyłkajtis

    There are many toxic substances used in our houses. Rodent poisons are not the most common group of substances, but cases of poisoning still occur. Long-acting anticoagulant rodenticides, also called superwarfarins, are known for their greater potency, longer half-life and delayed onset of symptoms. Cases of superwarfarin poisoning can pose a diagnostic and clinical challenge due to a wide array of presentations and prolonged severe coagulopathy requiring months of high-dose oral vitamin K therapy. The most common presentation of long-acting anticoagulant rodenticide poisoning is mucocutaneous bleeding, with other common presentations including haematuria, gingival bleeding, epistaxis and gastrointestinal bleeding.We discuss a case of self-poisoning with long-acting anticoagulant rodenticides with a little presentation of sympthoms and disscus about another cases based on the found articles.

  • Open Access

    Carbon monoxide poisoning - cases, pathophysiology, management

    by Magdalena Kubicka, Paweł Dębiec, Joanna Wilk, Przemysław Szydłowski, Magdalena Makarewicz, Mikołaj Porzak, Natalia Szyłkajtis

    Carbon monoxide poisoning is a common clinical problem, especially in autumn and winter. Carbon monoxide is an odorless, colorless gas and poisoning causes hypoxia, cell damage and consequently, can lead to death. Carbon monoxide exposure is measured directly from blood samples and expressed as a percentage of carboxyhemoglobin or indirectly using carbon monoxide in the breath. Carboxyhemoglobin percentage is the most commonly used biomarker of carbon monoxide exposure. Although the diagnosis of carbon monoxide poisoning can be confirmed by the detection of elevated levels of carboxyhemoglobin in the blood, the presence of clinical signs after known exposure to carbon monoxide should not be ignored. Carbon monoxide poisoning can have lasting effects. Physicians evaluating patients with acute poisoning should initiate treatment with normobaric oxygen and consider treatment with hyperbaric oxygen. Often, complete recovery after poisoning may not be possible and you should then refer for the treatment of complications to appropriate specialists.